Navigation Links
Surface Logix Raises $20 Million in Financing and Starts Phase 2b Clinical Trial of SLx-4090 in Dyslipidemia and Diabetes
Date:3/9/2009

BOSTON, March 9 /PRNewswire/ -- Surface Logix today announced that it has raised over $20 million in a combined equity and debt financing. The Company raised approximately $15 million through equity contributions by existing investors, including ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology Ventures and Venrock Associates. In addition, MPM Capital participated as a new investor. On top of the equity round, $5 million was raised through a venture loan from Silicon Valley Bank.

"This significant financing with top-quality investors is a testament to the strength of our clinical pipeline of drug candidates and our discovery capabilities," said Dr. Keith Dionne, CEO of Surface Logix. "We will use these proceeds to advance our novel metabolic and cardiovascular programs:

  • Complete Phase 2b studies for SLx-4090 in dyslipidemia, diabetes and obesity;
  • Formulate SLx-2101, our novel PDE-5 inhibitor, in preparation for Phase 2b trials in hypertension;
  • Complete first-in-human studies for SLx-2119, the lead compound in our selective ROCK inhibitor program; and
  • Advance two or more of our novel enteric discovery programs, targeting metabolic disorders, into development."

The Company also announced the start of a U.S.-based multicenter Phase 2b clinical trial to test the lipid-lowering effects of SLx-4090 in 135 patients with dyslipidemia. This three-month trial in overweight and obese patients will also study the effects of SLx-4090 on markers of diabetes and metabolic syndrome.

"We are excited to be moving into the next important phase in the clinical development of SLx-4090," commented Dr Warwick Tong, SVP of Development at Surface Logix. "This is the first of two complementary trials in dyslipidemia and diabetes that will study the safety, tolerability and clinical utility of SLx-4090 in a range of patients with metabolic and lipid disorders."

About SLx-4090 in Dyslipidemia, Diabetes and Obesity

SLx-4090 is a novel, oral, non-systemically available inhibitor of microsomal triglyceride transfer protein (MTP) that acts by blocking the formation of particles known as chylomicrons in enterocytes, thereby reducing the uptake of triglycerides and cholesterol into the lymphatic circulation and ultimately, the systemic circulation. Designed to exert its effect only in enterocytes, SLx-4090 avoids mechanistic toxicities in the liver (where MTP inhibition causes fatty liver) and other organs. MTP inhibitors that have been brought into development by others lack this critical feature and have therefore encountered significant toxicity concerns in the clinic, which will severely limit their therapeutic potential. SLx-4090 has potential not only in dyslipidemia but also in obesity and diabetes as a result of the compound's ability to restrict energy absorption by reducing the uptake of triglycerides. SLx-4090 has demonstrated an excellent safety profile in both clinical and pre-clinical studies.

About Surface Logix Inc.

Surface Logix Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs to treat metabolic and cardiovascular disease. For more information, please visit http://www.surfacelogix.com.

    Contact:

    Warwick Tong, MD
    Surface Logix Inc.
    Sr. Vice President, Corporate Development
    617.746.8505

    Media:
    Sarah Cavanaugh
    MacDougall Biomedical Communications Inc.
    781.235.3060


'/>"/>
SOURCE Surface Logix Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Clears New Skin and Surface Treatment Applicator for Use With Xofts Axxent(R) Electronic Brachytherapy (eBx) System
2. Study suggests surface water contaminated with salmonella more common than thought
3. Alternative Surface Disinfection Explored in Latest Issue of American Journal of Infection Control (AJIC)
4. Cradle to Cradle(SM) Digs Beneath the Surface with New Ingredient Certification
5. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
6. Hill-Rom Announces Agreement with Encompass Therapeutic Support Systems Adding New Surface Choice for Use with Hill-Rom Frames
7. Particle Sciences Develops Methods for Increasing Quality of Sintered Metal Products and for Coating Surfaces with Metal Oxide Films
8. Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage
9. GOCE Earth explorer satellite to look at the Earths surface and core
10. Measurement technique probes surface structure of gold nanocrystals
11. Large source of nitrate, a potential water contaminant, found in near-surface desert soils
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: